Wood P M, Proctor S J
Department of Haematology, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.
Leuk Res. 1990;14(5):395-9. doi: 10.1016/0145-2126(90)90024-4.
This article reviews the historical development of thalidomide as an immunosuppressive agent and the current state of knowledge of thalidomide as an anti-graft-versus-host disease (GVHD) agent. The evidence suggests that metabolites of thalidomide act at an early stage in the antigen recognition-activation pathway of graft T lymphocytes and down regulate normal lymphocyte responses. This effect seems to have beneficial effects in both acute and chronic GVHD, but the optimal mode of use in the clinical setting remains to be determined.
本文回顾了沙利度胺作为免疫抑制剂的历史发展以及沙利度胺作为抗移植物抗宿主病（GVHD）药物的当前知识状况。证据表明，沙利度胺的代谢产物在移植T淋巴细胞的抗原识别-激活途径的早期起作用，并下调正常淋巴细胞反应。这种作用似乎在急性和慢性GVHD中都有有益效果，但在临床环境中的最佳使用方式仍有待确定。
